Comparing the current results to its competitors, Bio Techne reported Revenue increase in the 4 quarter 2026 by 1.06 % year on year. The revenue growth was below Bio Techne's competitors' average revenue growth of 7.2 %, achieved in the same quarter.
Bio Techne's Comment on Competition and Industry Peers
The company intends to utilize its strong balance sheet to acquire new and differentiated technologies and products to enhance competitiveness, address customer workflow requirements, and enter adjacent markets. Growth will be pursued through innovation and acquisitions, focusing on expanding product offerings into emerging research areas and increasing presence in diagnostics and therapeutics markets. Acquisitions have played and will continue to play a key role in broadening the portfolio of innovative tools and bioactive reagents and facilitating entry into related markets. Additionally, the company plans to improve customer experience by expanding its sales team.
Competitors identified in company filings include Abcam plc., Agilent Technologies, BD Biosciences, Bio-Rad Laboratories, Danaher, Luminex, Merck KGaA, Merck KGaA/EMD Chemicals, Inc., Meso Scale Discovery, Millipore, Molecular Devices, PeproTech, Inc., PerkinElmer, Quanterix, Shimadzu, Tecan BioTek, Thermo Fisher Scientific, Inc., and Waters.
Repligen Corp operates as a bioprocessing company that provides products and services to the life sciences industry. They focus on the development, production, and distribution of highly specialized consumable products used in the manufacture of biological drugs. Repligen's business model revolves around helping their customers enhance productivity, improve quality, and reduce production costs in the biopharmaceutical manufacturing process.
Qiagen N.V. is a Dutch multinational company that operates in the field of molecular diagnostics and sample preparation technologies. Their business model revolves around developing and manufacturing products and solutions for molecular testing, enabling researchers and healthcare professionals to analyze biological samples and gain insights into diseases and genetic variations. Qiagen N.V. primarily generates revenue through the sale of instruments, consumables, and related services to customers in various market segments including academia, pharmaceuticals, and diagnostics.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Illumina Inc is a leading company in the genomics sector, focusing on next-generation sequencing technologies that enhance genetic analysis. Their business model encompasses a diverse range of products, including sequencing platforms, reagents, and bioinformatics solutions, which together facilitate comprehensive genomic studies for researchers. By integrating these tools, Illumina supports advancements in fields such as oncology, drug discovery, and personalized healthcare, positioning itself at the forefront of genomic innovation.
Bio-Rad Laboratories Inc operates as a global leader in life sciences and clinical diagnostics by focusing on the development, manufacturing, and distribution of a diverse array of products and solutions. Their business model emphasizes innovation, providing advanced tools and technologies that empower scientists and healthcare professionals to effectively analyze biological materials. By delivering high-quality solutions, Bio-Rad aims to facilitate scientific breakthroughs and enhance patient care in various healthcare settings.
Sources:
Bio techne Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bio techne Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
